Cannabichromene (CBC)

Cannabichromene, commonly abbreviated as CBC, is one of the over a hundred cannabinoids found in the Cannabis sativa plant, which includes marijuana and hemp. Discovered in the 1960s, CBC is considered one of the “big six” cannabinoids prominent in medical research. Unlike its more famous counterparts, tetrahydrocannabinol (THC) and cannabidiol (CBD), CBC is non-psychoactive, meaning it does not produce the “high” associated with THC. Its structure and formation arise from the same precursor as THC and CBD, the cannabigerolic acid (CBGA), before it is converted by specific enzymes in the plant to create the distinct compounds. CBC has attracted interest from the scientific community due to its potential therapeutic properties. Early research suggests that CBC may contribute to the analgesic, anti-inflammatory, and anti-viral effects of cannabis. It is also being studied for its possible role in promoting neurogenesis and as a potential anti-cancer agent. However, much of the research on CBC is still in its infancy, with a need for more comprehensive clinical trials to fully understand its effects and potential medical applications. As with other cannabinoids, the efficacy and safety of CBC are subjects of ongoing research, and it is currently less well-known and less commercially available than THC or CBD.